CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 76 enrolled
Drug / intervention
Stereotactic radiotherapyradiation
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04891874
NCT04891874N/ACompleted
CompareCT.gov

Adjuvant Stereotactic Body Radiation for Hepatocellular Carcinoma With Microvascular Invasion and Narrow Resection Margin

Eastern Hepatobiliary Surgery Hospital·interventional·Posted May 19, 2021·Updated Sep 10, 2021

In Brief

A clinical study evaluating Stereotactic radiotherapy for Hepatocellular Carcinoma. Completed, enrolled 76 participants across 1 site.

Detailed Summary

Positive micro vascular invasion in early stage hepatocellular carcinoma(HCC) leads to early recurrence after surgery. Adjuvant external radiotherapy will be applied in those patients to see if disease free survival and overall survival could be approved.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHepatocellular Carcinoma
CountriesChina
Collaborators--

Timeline

N/ACompletedFinished
20162017201820192020202120222023202420252026
First PostedMay 19, 2021
Enrollment StartAug 1, 2015
Primary CompletionDec 31, 2020
TodayJul 2, 2026
Enrollment to primary: 5.4 yearsPosted 5.1 years ago

Interventions

Stereotactic radiotherapyradiation

Radiation using stereotactic radiotherapy device.